About
Volpara Health, operating under the Lunit brand, is a leading medical AI software platform designed to revolutionize cancer detection and precision oncology. The platform's AI Radiology suite includes tools such as Lunit INSIGHT MMG for 2D and DBT 3D mammography analysis, Volpara Scorecard for breast density assessment, Volpara Risk Pathways for patient risk stratification, Volpara Analytics for quality management, and Lunit INSIGHT CXR for chest X-ray analysis. On the precision oncology side, Lunit SCOPE IO enables tumor microenvironment analysis, while the SCOPE IHC Suite provides quantification of biomarkers including HER2, PD-L1, and genotype prediction. The platform integrates seamlessly into existing radiology and oncology workflows, delivering real-time insights and live mammography reporting through a connected Patient Hub. It is used by radiologists, oncologists, biopharma researchers, and clinical trial teams worldwide. With 700+ publications and 100+ industry partnerships, Volpara/Lunit supports both clinical practice and drug development—accelerating companion diagnostics and biomarker strategies at unprecedented speed and scale. The software is purpose-built for enterprise healthcare organizations seeking to improve screening accuracy, reduce missed cancers, and unlock precision treatment decisions across diverse patient populations.
Key Features
- AI Mammography Analysis: Lunit INSIGHT MMG and DBT solutions analyze 2D and 3D mammography images to identify the smallest cancers that might otherwise be missed, improving detection rates for radiologists.
- Breast Density & Risk Assessment: Volpara Scorecard and Risk Pathways tools automatically assess breast density and stratify patient risk, enabling personalized screening recommendations.
- Precision Oncology Biomarker Analysis: Lunit SCOPE IHC Suite quantifies oncology biomarkers including HER2, PD-L1, and tumor microenvironment features to support companion diagnostics and treatment decisions.
- Chest X-ray AI (Lunit INSIGHT CXR): Automated chest X-ray analysis detects abnormalities at scale, supporting high-volume radiology workflows with consistent, reliable AI-assisted reads.
- Analytics & Quality Management: Volpara Analytics provides live reporting, performance dashboards, and quality management tools to monitor and optimize screening program outcomes.
Use Cases
- Radiology departments using AI-assisted mammography reading to detect breast cancers earlier and reduce false negatives in routine screening programs.
- Hospital networks implementing automated chest X-ray analysis to manage high volumes of imaging studies with consistent AI-powered abnormality detection.
- Oncology centers leveraging tumor microenvironment and biomarker analysis tools to guide immunotherapy treatment decisions and personalize patient care.
- Biopharma companies integrating AI biomarker quantification into Phase II/III clinical trials to evaluate drug efficacy and develop companion diagnostics.
- Breast imaging programs using Volpara Risk Pathways and Scorecard to stratify patient risk and tailor supplemental screening recommendations based on breast density.
Pros
- Clinically Validated at Scale: With 700+ publications and deployments across 10,000+ sites in 65+ countries, the platform has extensive real-world evidence supporting its clinical effectiveness.
- End-to-End Cancer Care Coverage: From screening mammography and chest X-ray to precision oncology biomarker analysis, the platform covers the full cancer care pathway in one connected ecosystem.
- Biopharma & Clinical Trial Ready: Purpose-built tools for clinical trial integration and companion diagnostics make it a strong partner for pharmaceutical innovation and drug development programs.
Cons
- Enterprise-Only Pricing: The platform is targeted at large healthcare organizations and biopharma companies; pricing is not publicly available and likely high for smaller clinics.
- Complex Implementation: Integrating AI into existing radiology and oncology workflows may require significant IT support, training, and vendor coordination, increasing time to deployment.
Frequently Asked Questions
What is Volpara Health and its relationship with Lunit?
Volpara Health was acquired by Lunit, a South Korean medical AI company. The combined entity now operates under the Lunit brand, integrating Volpara's breast imaging and analytics tools with Lunit's broader cancer detection and precision oncology AI platform.
What types of cancer does the platform focus on?
The platform primarily focuses on breast cancer (via mammography AI and risk assessment) and lung/chest conditions (via chest X-ray AI), as well as broader oncology biomarker analysis for various cancers through the SCOPE IHC Suite.
Can the AI integrate with existing radiology systems?
Yes. The platform is designed to integrate seamlessly into existing clinical workflows and imaging systems, supporting radiologists without requiring a complete overhaul of their current infrastructure.
Is the platform suitable for clinical trials and biopharma research?
Absolutely. Lunit offers dedicated biopharma partnership programs where its AI biomarker analysis tools are used to support oncology clinical trials, accelerate companion diagnostic development, and enable global deployment of precision medicine strategies.
How many organizations use Volpara/Lunit globally?
The platform is trusted by 10,000+ customer sites across 65+ countries, supported by 100+ industry partnerships and validated through 700+ scientific publications.
